Skip to main content
Premium Trial:

Request an Annual Quote

Canadian Investor Grants Warnex Three Months to Repay $500K

NEW YORK (GenomeWeb News) – The genetic testing, molecular diagnostics, and lab services company Warnex said today it has been granted a waiver from an investor for the repayment of $500,000 it owes as a quarterly capital investment payment that was due today. 
Warnex said SIPAR, a Montreal-based investment company, has given it until April 1 to make this payment. Warnex also said the agreement is part of a strategy it announced last month to restructure its debts and reorganize its financing in order to stabilize its balance sheet.
Warnex CEO Mark Busgang said the agreement shows SIPAR’s “confidence in our ability to reorganize our financial instruments.”

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.